Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10230212 | 0.83 | CKS1B (0.59) | NAMPTCKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL4838151 | 0.83 | MAPT (0.47) | MAPTALDH1A1MCL1KDM4ETDP1 | |
| SCHEMBL10230218 | 0.83 | CKS1B (0.59) | NAMPTCKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL15728295 | 0.82 | TRPA1 (0.54) | NAMPTCKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL16394312 | 0.79 | CKS1B (0.53) | NAMPTCKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL25081246 | 0.78 | SUV39H2 (0.51) | NAMPTCKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL29311592 | 0.78 | CKS1B (0.53) | NAMPTCKS1BSKP1SKP2MAPT | |
| SCHEMBL12916519 | 0.78 | GPR119 (0.57) | NAMPTCKS1BSKP1SKP2KDM4E | |
| SCHEMBL10232262 | 0.77 | NAMPT (0.55) | NAMPTCKS1BSKP1SKP2MAPT | |
| SCHEMBL8222029 | 0.77 | CKS1B (0.53) | NAMPTCKS1BSKP1SKP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299104-B2 | Melanin hormone antagonist; therapy for obesity, type-2 diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7319108-B2 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-15 | — | — | US | disclosed |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | CYP11B1, CYP11B2, GPR119 | NAMPT 156/4885CKS1B 3977/4885SKP1 1704/4885 |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | NAMPT 156/4885CKS1B 3977/4885SKP1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.